Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease
Open Access
- 1 August 2011
- journal article
- Published by Elsevier BV in Kidney International
- Vol. 80 (3), 288-294
- https://doi.org/10.1038/ki.2011.49
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysisCMAJ : Canadian Medical Association Journal, 2009
- Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemiaKidney International, 2009
- Stroke and cancer: a reviewActa Neurologica Scandinavica, 2009
- External Validity of Clinical Trials in Acute Myocardial InfarctionArchives of Internal Medicine, 2007
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseThe New England Journal of Medicine, 2006
- Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and AnemiaThe New England Journal of Medicine, 2006
- Kidney function and anemia as risk factors for coronary heart disease and mortality: The Atherosclerosis Risk in Communities (ARIC) StudyAmerican Heart Journal, 2006
- External validity of randomised controlled trials: “To whom do the results of this trial apply?”The Lancet, 2005
- Predictive cardiovascular risk factors in patients with chronic kidney disease (CKD)Kidney International, 2005
- Validating Administrative Data in Stroke ResearchStroke, 2002